Sec Form 4 Filing - Liu Lina @ Yubo International Biotech Ltd - 2021-01-14-05:00

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Liu Lina 2. Issuer Name and Ticker or Trading Symbol Yubo International Biotech Ltd [ YBGJ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO, Treasurer and Secretary (Last) (First) (Middle) YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, XISHIKU AVENUE 3. Date of Earliest Transaction (MM/DD/YY) 01/14-05:00/2021 (Street) XICHENG DISTRICT, BEIJING, F400000 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 01/14-05:00/2021 D 116,697,438 D $ 0 ( 1 ) 0 D Class A Common Stock 01/14-05:00/2021 P 13,829,400 A $ 0 ( 2 ) 13,829,400 I By Focus Draw Group ( 3 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Liu Lina YUBO INTERNATIONAL BIOTECH LIMITED ROOM 105, BUILDING 5, XISHIKU AVENUE XICHENG DISTRICT, BEIJING, F400000 CFO, Treasurer and Secretary Signatures /s/ Lina Liu, CFO, Treasurer and Secretary 01/20-05:00/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares reported herein were surrendered to the issuer and canceled in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd.("Platinum"),Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. No cash consideration was paid in connection with surrender and cancellation of the shares. ( 2 )The shares reported herein were acquired in connection with an exchange transaction by and among Platinum International Biotech Co., Ltd. ("Platinum"), Yubo International Biotech (Beijing) Limited, the Reporting Person and certain other stockholders of Platinum. The Issuer issued the shares reported herein to the Reporting Person in exchange for the Reporting Person's equity interest in Platinum. No cash consideration was paid in connection with the exchange transaction. ( 3 )The shares are held by Focus Draw Group, of which the reporting person is the sole director. The Reporting Person disclaims beneficial ownership of the securities except to the extent of her pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.